The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes
Open accessAbstract
Inhibitors of dipeptidyl peptidase-4 (DPP-4), a key regulator of the actions of incretin hormones, exert antihyperglycemic effects in type 2 diabetic patients. A major unanswered question concerns the potential ability of DPP-4 inhibition to have beneficial disease-modifying effects, specifically to attenuate loss of pancreatic β-cell mass and function. Here, we investigated the effects of a potent and selective DPP-4 inhibitor, an analog of sitagliptin (des-fluoro-sitagliptin), on glycemic control and pancreatic β-cell mass and function in a mouse model with defects in insulin sensitivity and secretion, namely high-fat diet (HFD) streptozotocin (STZ)-induced diabetic mice. Significant and dose-dependent correction of postprandial and fasting hyperglycemia, HbA1c, and plasma triglyceride and free fatty acid levels were observed in HFD/STZ mice following 2–3 months of chronic therapy. Treatment with des-fluoro-sitagliptin dose dependently increased the number of insulin-positive β-cells in islets, leading to the normalization of β-cell mass and β-cell–to–α-cell ratio. In addition, treatment of mice with des-fluoro-sitagliptin, but not glipizide, significantly increased islet insulin content and improved glucose-stimulated insulin secretion in isolated islets. These findings suggest that DPP-4 inhibitors may offer long-lasting efficacy in the treatment of type 2 diabetes by modifying the courses of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Method for the Isolation of Intact Islets of Langerhans from the Rat Pancreas
Lacy, P. E., & Kostianovsky, M. (1967) · Diabetes · doi:10.2337/diab.16.1.35 · Cited by 2,751
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications
Unger, R. H. (1995) · Diabetes · doi:10.2337/diab.44.8.863 · Cited by 1,100
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Self-citationZhou, Y. P., & Grill, V. E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117042 · Cited by 677
Self-citationSelective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020735 · Cited by 649
Villhauer, E. B., Brinkman, J. A., Naderi, G. B., Burkey, B. F., Dunning, B. E., Prasad, K., Mangold, B. L., Russell, M. E., & Hughes, T. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030091l · Cited by 613
Lupi, R., Dotta, F., Marselli, L., Del Guerra, S., Masini, M., Santangelo, C., Patané, G., Boggi, U., Piro, S., Anello, M., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1437 · Cited by 595
β-cells in type II diabetes mellitus
Porte, D. (1991) · Diabetes · doi:10.2337/diab.40.2.166 · Cited by 585
Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Pick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., & Polonsky, K. S. (1998) · Diabetes · doi:10.2337/diabetes.47.3.358 · Cited by 551
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.-M., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J., & Wagtmann, N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120069197 · Cited by 538
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502
Diabetes mellitus and genetically programmed defects in β-cell function
Bell, G. I., & Polonsky, K. S. (2001) · Nature · doi:10.1038/414788a · Cited by 475
CD26, let it cut or cut it down
De Meester, I., Korom, S., Van Damme, J., & Scharpé, S. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01486-3 · Cited by 451
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421
Butler, A. E., Janson, J., Soeller, W. C., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.9.2304 · Cited by 411
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
Conarello, S. L., Li, Z., Ronan, J., Roy, R. S., Zhu, L., Jiang, G., Liu, F., Woods, J., Zycband, E., Moller, D. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0631828100 · Cited by 347
Self-citationPospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309
Deconstructing Type 2 Diabetes
Taylor, S. I. (1999) · Cell · doi:10.1016/s0092-8674(00)80709-6 · Cited by 307
Tourrel, C., Bailbe, D., Lacorne, M., Meile, M.-J., Kergoat, M., & Portha, B. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1443 · Cited by 285
Lambeir, A.-M., Proost, P., Durinx, C., Bal, G., Senten, K., Augustyns, K., Scharpé, S., Van Damme, J., & De Meester, I. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103106200 · Cited by 271
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
Pospisilik, J. A., Stafford, S. G., Demuth, H.-U., Brownsey, R., Parkhouse, W., Finegood, D. T., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.943 · Cited by 232
Nongenetic mouse models of non—insulin-dependent diabetes mellitus
Luo, J., Quan, J., Tsai, J., Hobensack, C. K., Sullivan, C., Hector, R., & Reaven, G. M. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90027-0 · Cited by 224
The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides
Zhu, L., Tamvakopoulos, C., Xie, D., Dragovic, J., Shen, X., Fenyk-Melody, J. E., Schmidt, K., Bagchi, A., Griffin, P. R., Thornberry, N. A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212355200 · Cited by 221
Self-citationTrumper, A., Trumper, K., & Horsch, D. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1740233 · Cited by 193
Montaña, E., Bonner-Weir, S., & Weir, G. C. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116297 · Cited by 193
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
Nauck, M. A., & Meier, J. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.014 · Cited by 180
Sudre, B., Broqua, P., White, R. B., Ashworth, D., Evans, D. M., Haigh, R., Junien, J.-L., & Aubert, M. L. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1461 · Cited by 165
Ehses, J. A., Casilla, V. R., Doty, T., Pospisilik, J. A., Winter, K. D., Demuth, H.-U., Pederson, R. A., & McIntosh, C. H. S. (2003) · Endocrinology · doi:10.1210/en.2002-0068 · Cited by 159
Pauly, R. P., Rosche, F., Wermann, M., McIntosh, C. H. S., Pederson, R. A., & Demuth, H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23222 · Cited by 154
Banting lecture 1990. Beta-cells in type II diabetes mellitus
Porte, D. (1991) · Diabetes · doi:10.2337/diabetes.40.2.166 · Cited by 150
Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes
Mest, H. ‐., & Mentlein, R. (2005) · Diabetologia · doi:10.1007/s00125-005-1707-5 · Cited by 141
Åhrén, B., & Hughes, T. E. (2004) · Endocrinology · doi:10.1210/en.2004-1174 · Cited by 108
Zimmerman, B. R. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70264-4 · Cited by 99
Glucagon-like Peptide-1, A Gastrointestinal Hormone with a Pharmaceutical Potential
Holst, J. J. (1999) · Current Medicinal Chemistry · doi:10.2174/092986730611220401163238 · Cited by 73
Desensitization of insulin secretion
Rustenbeck, I. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00996-6 · Cited by 60
Zhou, Y., Marlen, K., Palma, J. F., Schweitzer, A. C., Reilly, L., Gregoire, F. M., Xu, G. G., Blume, J. E., & Johnson, J. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307972200 · Cited by 59
Self-citationDeacon, C. F., & Holst, J. J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00359-5 · Cited by 55
Harnessing the Therapeutic Potential of Glucagon-Like Peptide-1: A Critical Review
Baggio, L. L., & Drucker, D. J. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201020-00005 · Cited by 35
Deacon, C. F. (2005) · PubMed · Cited by 31
Buse, J. B. (1999) · PubMed · Cited by 26
Structure of CD26 (Dipeptidyl Peptidase IV) and Function in Human T Cell Activation
Hegen, M., Kameoka, J., Dong, R.-P., Morimoto, C., & Schlossman, S. F. (1997) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-9613-1_15 · Cited by 21
Barlocco, D. (2004) · PubMed · Cited by 14
UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years
UK Prospective Diabetes Study (UKPDS) Group, Matthews, D. R., Cull, C. A., Stratton, I. M., Holman, R. R., & Turner, R. C. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199804)15:4
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Song, B., Scheuner, D., Ron, D., Pennathur, S., & Kaufman, R. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34587 · Cited by 693
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614
Metadata
- Authors
- Mu, J., Woods, J., Zhou, Y.-P., Roy, R. S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A. D., Moller, D. E., Thornberry, N. A., & Zhang, B. B.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2006-06-01
- Volume
- 55
- Issue
- 6
- Pages
- 1695-1704
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2106558322
- Cited by
- 449
- References
- 49
- FWCI
- 23.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.